This study is to evaluate the food effect (FE) on the PK of 200 mg CX11 in healthy participants
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
32
CX11 (VCT220) administered orally to participants who are in fasted/fed state in the first 6 consecutive days, and in fed/fasted state on the 7th day
Shanghai Xuhui Central Hospital
Shanghai, Shanghai Municipality, China
Area Under the Concentration-time curve from 0 to 24 hour (AUC0-24) of CX11 (VCT220)
AUC0-24 of of CX11 (VCT220)
Time frame: Predose at Day1 up to 35 days postdose
Maximum Observed Concentration (Cmax) of CX11 (VCT220)
Cmax of CX11 (VCT220)
Time frame: Predose at Day1 up to 35 days postdose
Time to Maximum Observed Concentration (Tmax) of CX11 (VCT220)
Tmax of CX11 (VCT220)
Time frame: Predose at Day 1 up to 35 days postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.